Network pharmacology research and experimental validation of Qishen decoction in the treatment of non-alcoholic fatty liver disease
Objective: To screen the main active components of Qishen decoction by network pharmacology and predict the target of its treatment for nonalcoholic fatty liver disease (NAFLD), and to verify it by experiments. Methods: The main active components of Qishen decoction and the disease target of NAFL...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Editorial Board of Journal of Hainan Medical University
2020-07-01
|
Series: | Journal of Hainan Medical University |
Subjects: | |
Online Access: | http://www.hnykdxxb.com/PDF/202014/07.pdf |
id |
doaj-822bc5d750dc4e6f9493d8c7a5fa69cc |
---|---|
record_format |
Article |
spelling |
doaj-822bc5d750dc4e6f9493d8c7a5fa69cc2020-11-25T03:34:51ZengEditorial Board of Journal of Hainan Medical UniversityJournal of Hainan Medical University1007-12371007-12372020-07-0126143238Network pharmacology research and experimental validation of Qishen decoction in the treatment of non-alcoholic fatty liver diseaseShuo-Xi Li0Bing-Yu Wang1Jiamusi College of Heilongjiang University of traditional Chinese medicine, Jiamusi, Heilongjiang Province, 154000Nangang Branch of Heilongjiang Academy of traditional Chinese medicine, Harbin, Heilongjiang, 1500001Objective: To screen the main active components of Qishen decoction by network pharmacology and predict the target of its treatment for nonalcoholic fatty liver disease (NAFLD), and to verify it by experiments. Methods: The main active components of Qishen decoction and the disease target of NAFLD were screened through the database; the drug disease target network and PPI were constructed by the software of Cytoscape and string database; the enrichment of go and KEGG were analyzed by the database of DAVID; HE staining, red oil O staining, serum biochemical index and Western blot were used to verify the effect mechanism of Qishen Decoction on NAFLD. Results: A total of 207 active compounds and 95 drug- disease-targets of Qishen Decoction were selected in this study. The results of KEGG enrichment analysis showed that the mechanism of Qishen decoction in the treatment of NAFLD involved adipocytokines, insulin signaling pathway, fatty acid biosynthesis, etc. The results showed that Qishen decoction could significantly reduce the liver NAS score and oil red O staining area of NAFLD rats (P<0.05). At meanwhile, Qishen decoction significantly reduced the levels of serum glucose, insulin, HOMA-IR, TC, TG, AST and ALT in NAFLD rats (P<0.05). In addition, Qishen decoction can significantly up regulate the expression of p-INSR β in liver tissue, down regulate the expression of SREBP-1c, Fas and p-ACC (P<0.05). Conclusion: Qishen decoction can improve the insulin resistance of NAFLD rats through insulin signaling pathway, so as to improve NAFLD fat deposition and liver injury. In addition, Qishen decoction can also achieve the therapeutic effect of NAFLD through multiple channels and targets.http://www.hnykdxxb.com/PDF/202014/07.pdfnetwork pharmacologyqishen decoctionnonalcoholic fatty liver diseaseinsulin signaling pathwaymolecular mechanism |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Shuo-Xi Li Bing-Yu Wang |
spellingShingle |
Shuo-Xi Li Bing-Yu Wang Network pharmacology research and experimental validation of Qishen decoction in the treatment of non-alcoholic fatty liver disease Journal of Hainan Medical University network pharmacology qishen decoction nonalcoholic fatty liver disease insulin signaling pathway molecular mechanism |
author_facet |
Shuo-Xi Li Bing-Yu Wang |
author_sort |
Shuo-Xi Li |
title |
Network pharmacology research and experimental validation of Qishen decoction in the treatment of non-alcoholic fatty liver disease |
title_short |
Network pharmacology research and experimental validation of Qishen decoction in the treatment of non-alcoholic fatty liver disease |
title_full |
Network pharmacology research and experimental validation of Qishen decoction in the treatment of non-alcoholic fatty liver disease |
title_fullStr |
Network pharmacology research and experimental validation of Qishen decoction in the treatment of non-alcoholic fatty liver disease |
title_full_unstemmed |
Network pharmacology research and experimental validation of Qishen decoction in the treatment of non-alcoholic fatty liver disease |
title_sort |
network pharmacology research and experimental validation of qishen decoction in the treatment of non-alcoholic fatty liver disease |
publisher |
Editorial Board of Journal of Hainan Medical University |
series |
Journal of Hainan Medical University |
issn |
1007-1237 1007-1237 |
publishDate |
2020-07-01 |
description |
Objective: To screen the main active components of Qishen decoction by network
pharmacology and predict the target of its treatment for nonalcoholic fatty liver disease
(NAFLD), and to verify it by experiments. Methods: The main active components of Qishen
decoction and the disease target of NAFLD were screened through the database; the drug
disease target network and PPI were constructed by the software of Cytoscape and string
database; the enrichment of go and KEGG were analyzed by the database of DAVID; HE
staining, red oil O staining, serum biochemical index and Western blot were used to verify the
effect mechanism of Qishen Decoction on NAFLD. Results: A total of 207 active compounds
and 95 drug- disease-targets of Qishen Decoction were selected in this study. The results of
KEGG enrichment analysis showed that the mechanism of Qishen decoction in the treatment
of NAFLD involved adipocytokines, insulin signaling pathway, fatty acid biosynthesis, etc.
The results showed that Qishen decoction could significantly reduce the liver NAS score and
oil red O staining area of NAFLD rats (P<0.05). At meanwhile, Qishen decoction significantly
reduced the levels of serum glucose, insulin, HOMA-IR, TC, TG, AST and ALT in NAFLD
rats (P<0.05). In addition, Qishen decoction can significantly up regulate the expression of
p-INSR β in liver tissue, down regulate the expression of SREBP-1c, Fas and p-ACC (P<0.05).
Conclusion: Qishen decoction can improve the insulin resistance of NAFLD rats through
insulin signaling pathway, so as to improve NAFLD fat deposition and liver injury. In addition,
Qishen decoction can also achieve the therapeutic effect of NAFLD through multiple channels
and targets. |
topic |
network pharmacology qishen decoction nonalcoholic fatty liver disease insulin signaling pathway molecular mechanism |
url |
http://www.hnykdxxb.com/PDF/202014/07.pdf |
work_keys_str_mv |
AT shuoxili networkpharmacologyresearchandexperimentalvalidationofqishendecoctioninthetreatmentofnonalcoholicfattyliverdisease AT bingyuwang networkpharmacologyresearchandexperimentalvalidationofqishendecoctioninthetreatmentofnonalcoholicfattyliverdisease |
_version_ |
1724557157478694912 |